## Phenotypes Work Group Recommendations for Harmonization and Standardization

## **Opioid Use**

- 1. All non-IV fills of:
  - a. Codeine
  - b. Fentanyl
  - c. Hydrocodone
  - d. Hydromorphone
  - e. Morphine
  - f. Oxycodone
  - g. Oxymorphone
  - h. Tramadol
- 2. All non-IV, pill/tablet pills of:
  - a. Methadone
- 3. All transdermal or buccal fills of:
  - a. Buprenorphine

## Additional parameters applied to characterize opioids use:

- 1. Number supplied
- 2. Days supplied
- 3. a/b x conversion factor = milligrams morphine equivalent daily dose (MEDD)
- 4. mg MEDD at enrollment
- 5. mg MEDD monthly during enrollment and at study completion
- 6. Total mg MEDD supplied in year before enrollmen

**Long-Term Opioid Use** is defined as prescription of an opioid medication over a 90-day total period, with a maximum allowable gap of up to 30 days between fills.

Edelman EJ, Gordon K, Becker WC, Goulet JL, Skanderson M, Gaither JR, et al. Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med. 2013;28(1):82–90.